Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes.
Myelodysplastic syndromes are clonal hematopoietic stem cell disorders. Their exact etiology is unknown. Myelodysplastic syndromes cause progressive bone marrow failure resulting in pancytopenia and refractory, transfusion-dependent anemia. One can observe typical morphological alterations in the erythroid, myeloid and/or megakaryocytic cell lineage. Blast counts may also be increased. The pathologic cells are genetically unstable, and a myelodysplastic syndrome might transform into acute myeloid leukemia. The overall survival of these diseases range between few months to around ten years. Correct diagnosis and accurate prognostic classification is essential. In the past decades several scoring systems were established beginning with the French-American-British classification to the most recent Revised International Prognostic Scoring System. In all of these classifications bone marrow morphology is still the most important factor, though nowadays the genetic aberrations and flow cytometry findings are also included. The diagnosis and prognostic classification of myelodysplastic syndromes remain a great challenge for hematologists.
Department of Laboratory Medicine, University of Debrecen , Debrecen H-4032, Hungary.
Bettina
B
Kárai
Department of Laboratory Medicine, University of Debrecen , Debrecen H-4032, Hungary.
Eszter
E
Szánthó
Department of Laboratory Medicine, University of Debrecen , Debrecen H-4032, Hungary.
János
J
Kappelmayer
Department of Laboratory Medicine, University of Debrecen , Debrecen H-4032, Hungary.
Zsuzsa
Z
Hevessy
classification system; flow cytometry; myelodysplastic syndromes; prognostic scoring system
Blood. 2002 Oct 1;100(7):2292-302
12239137
Haematologica. 2012 Jun;97(6):895-902
22271903
Nature. 1974 Oct 4;251(5474):437-8
4421285
Cancer. 2007 Apr 15;109(8):1536-42
17345612
Am J Cancer Res. 2011;1(4):531-41
21984971
Leuk Res. 2012 Jan;36(1):1-5
21920601
Blood. 2009 Jul 30;114(5):937-51
19357394
J Natl Compr Canc Netw. 2011 Jan;9(1):30-56
21233243
Blood. 2003 Jul 1;102(1):394-403
12649150
Curr Cancer Drug Targets. 2007 Sep;7(6):541-58
17896920
Leukemia. 2012 Jul;26(7):1730-41
22307178
J Clin Oncol. 2012 Mar 10;30(8):820-9
22331955
Blood. 2004 Nov 1;104(9):2722-7
15198950
Acta Haematol. 1997;97(3):127-31
9066706
Br J Haematol. 1982 Jun;51(2):189-99
6952920
Leuk Res. 2009 Feb;33(2):326-31
18718658
Blood. 2012 Sep 20;120(12):2454-65
22740453
Leuk Res. 2007 Jun;31(6):727-36
17257673
Blood. 1997 Mar 15;89(6):2079-88
9058730
J Clin Oncol. 2007 Aug 10;25(23):3503-10
17687155
Haematologica. 2008 Nov;93(11):1712-7
18838480
Leuk Res. 2004 Nov;28(11):1171-5
15380341
Methods Cell Biol. 2004;75:559-76
15603442
Ann Intern Med. 1974 Apr;80(4):470-6
4220265